Risk Factors Update Summary
- Net loss increased from $92.1 million to $117.9 million in 2023.
- Inclusion of heightened interest rates and inflation as potential risks to financial performance.
- Accumulated deficit rose from $222 million to $340 million as of December 31, 2023.
- Addition of risks related to Russia-Ukraine and Israel-Hamas wars may impact operations in those regions.
- Cash, cash equivalents, and marketable securities decreased from $230.2 million to $137.2 million.
- Mention of potential future pandemics as a risk factor for the company's operations.
- Gross federal net operating loss carryforwards increased from $153.6 million to $190.2 million.
- Local net operating loss carryforwards rose from $141.1 million to $180.8 million.
- The company transitioned from "trem-cel" to "trem-cel and VCAR33ALLO" as product candidates.
- The company initiated clinical development of VCAR33ALLO in patients with relapsed or refractory AML.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1817229&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.